Skip to main content

Big Data Analysis Firm Ayasdi Raises $30.6M in Series B Financing

NEW YORK (GenomeWeb News) – Big data analysis firm Ayasdi said this week it raised $30.6 million in a Series B funding round.

Institutional Venture Partners led the round. Additional participants included Citi Ventures, GE Ventures, and existing investors Khosla Ventures and Floodgate.

In conjunction with the investment, IVP's Steve Harrick is joining Ayasdi's board.

The funding will go toward acceleration of the Palo Alto, Calif.-based company's development of machine learning systems and topological data analysis –based approaches.

Founded in 2008, Ayasdi is a spinout of Stanford University and has developed a platform called Ayasi Iris "to automatically find insights from complex data and operationalize them." The method combines advanced machine learning techniques with toplological data analysis, which is a branch of mathematics, to discover insights without coding scripting, or manual querying.

The first version of the platform was launched in 2011 and Ayasdi initially sold it to clients in the pharmaceutical space and government organizations, such as the US Food and Drug Administration, a company official told BioInform earlier this year.

Other clients include the, Merck, the Mt. Sinai Medical Center, and the University of California, San Francisco.

Ayasdi raised about $10.3 million in a Series A financing round in January.

Filed under

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.